Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Knock Six Years Off Your Timeline. Um.

    There’s only one honest answer to the question “How long does it take to develop a new drug?”, and that’s “Too @#$! long”. In the same way, the only honest answer to “What are the average chances for a drug candidate’s success?” is “Too @#$! low”. The combination of those two factors… Read More
  • Alzheimer's Disease

    Bad News – But Not the Unexpected Kind

    Yesterday was not a good day for small companies trying to get drugs to regulatory approval for tough diseases. You may well remember Axovant, a company that I’ve written about several times (most recently here). To recap, AXON was started by a fund manager, who bought a failed Alzheimer’s candidate off GSK, announced that they’d… Read More
  • Business and Markets

    It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a response to the Tufts estimates on these costs, and I’m not going to help much, because I have some things to debate about this paper myself. The authors… Read More
  • Business and Markets

    Allergan Pulls A Fast One

    Friday brought news of a drug-company maneuver that I had never heard of, and didn’t even realize was possible. First, a bit of background; the stage needs to be set properly. One of Allergan’s products is Restasis, used for dry eyes, which is an opthalmic formulation of cyclosporine. It’s a valuable part of their portfolio… Read More
  • Business and Markets

    Lilly Cuts Back, Again

    The Big Pharma story at the moment, sad to say, is that Eli Lilly is shedding a lot of employees: 3,500 or so (2000 of them in the US), about 8.5% of their global workforce. Their site in Bridgewater (NJ) is being closed, and interestingly, so is their site in Shanghai, which makes them (if… Read More
  • Biological News

    Good Craziness and Bad Craziness

    It’s fair to say that there’s a high level of excitement these days in biopharma (and the associated academic disciplines) due to the tools we have at our disposal these days. CRISPR and other gene-editing technologies, new looks at RNA, chromatin, and epigenetics, all sorts of unusual modes for altering cells and whole-animal phenotype… Read More
  • Business and Markets

    GSK Rearranges, Once More

    There have been a lot of announcements in the biopharma field this week, and I’m just now getting around to GlaxoSmithKline’s from a couple of days ago. The company announced that they’re dropping 30 R&D programs and refocusing the ones that are left. Cancer and immunology are now back in favor, and rare disease programs… Read More
  • Business and Markets

    AstraZeneca Gets the Bad News

    After writing about Merck’s successes (so far) in immuno-oncology, it’s time to write about AstraZeneca’s failure. When the rumors started flying about Pascal Soriot leaving the company, one of the speculations was that the MYSTIC trial of the company’s PD-L1 (Imfinzi, durvalumab) and CTLA4 (trememelimab) therapies might be… Read More
  • Business and Markets

    Chaos at AstraZeneca

    What on earth is going on over at AstraZeneca? The company has had plenty of wild ups and downs over the years, and managed to fight off a takeover attempt by Pfizer (and who else has managed that?) But in doing so, they made some pretty strong revenue projections (look what we’ll do if Pfizer… Read More
  • Biological News

    Hemophilia: A Proving Ground For Genetic Disease

    There’s very good news for Alnylam (and their partner Sanofi) this morning. They’ve been working on an RNAi approach to hemophilia (fitusiran), targeting expression of antithrombin, a protein which as the name implies which keeps blood from clotting by several different mechanisms. The clinical data that have just come out look very en… Read More
...234...